SG11201912161SA - Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues - Google Patents
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analoguesInfo
- Publication number
- SG11201912161SA SG11201912161SA SG11201912161SA SG11201912161SA SG11201912161SA SG 11201912161S A SG11201912161S A SG 11201912161SA SG 11201912161S A SG11201912161S A SG 11201912161SA SG 11201912161S A SG11201912161S A SG 11201912161SA SG 11201912161S A SG11201912161S A SG 11201912161SA
- Authority
- SG
- Singapore
- Prior art keywords
- glp
- glucagon
- analogues
- peptide
- administration
- Prior art date
Links
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709643.9A GB201709643D0 (en) | 2017-06-16 | 2017-06-16 | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues |
| GBGB1714203.5A GB201714203D0 (en) | 2017-09-05 | 2017-09-05 | Dosage regimes for the administration of Glucagon-Like Peptide-2(GLP-2)Analogues |
| GBGB1800873.0A GB201800873D0 (en) | 2018-01-19 | 2018-01-19 | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues |
| PCT/EP2018/065951 WO2018229252A1 (en) | 2017-06-16 | 2018-06-15 | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912161SA true SG11201912161SA (en) | 2020-01-30 |
Family
ID=62748940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912161SA SG11201912161SA (en) | 2017-06-16 | 2018-06-15 | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20200000883A1 (en) |
| EP (3) | EP4424362A2 (en) |
| JP (2) | JP7200238B2 (en) |
| KR (2) | KR102504200B1 (en) |
| CN (2) | CN111032072A (en) |
| AU (2) | AU2018285580B2 (en) |
| BR (1) | BR112019026711A2 (en) |
| CA (1) | CA3066523A1 (en) |
| CL (1) | CL2019003660A1 (en) |
| CO (1) | CO2019014028A2 (en) |
| DK (2) | DK3881861T3 (en) |
| ES (1) | ES2894629T3 (en) |
| IL (2) | IL299864B2 (en) |
| MX (2) | MX2019015054A (en) |
| PE (1) | PE20200678A1 (en) |
| SG (1) | SG11201912161SA (en) |
| TW (1) | TWI791539B (en) |
| WO (1) | WO2018229252A1 (en) |
| ZA (1) | ZA201908355B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4041722A4 (en) | 2019-10-07 | 2023-12-13 | Kallyope, Inc. | Gpr119 agonists |
| CN116323608A (en) | 2020-05-19 | 2023-06-23 | 卡尔优普公司 | AMPK activator |
| CN111560061A (en) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | Preparation method of Gelpaglutide |
| CN116390925A (en) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | AMPK activator |
| KR20230121853A (en) | 2020-12-16 | 2023-08-21 | 질랜드 파마 에이/에스 | Use of GLP-2 analogues in patients with renal insufficiency |
| EP4398872A1 (en) | 2021-09-10 | 2024-07-17 | Zealand Pharma A/S | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues |
| WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| WO2023132609A1 (en) * | 2022-01-05 | 2023-07-13 | 주식회사 휴온스랩 | Long-acting fatty acid-peptide derivative and use thereof |
| IL315200A (en) * | 2022-02-24 | 2024-10-01 | Entera Bio Ltd | Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-2 |
| WO2024068933A1 (en) | 2022-09-30 | 2024-04-04 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| WO2024156884A1 (en) | 2023-01-27 | 2024-08-02 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| JP5197012B2 (en) * | 2004-11-01 | 2013-05-15 | エヌピーエス ファーマシューティカルズ インコーポレイテッド | Treatment of patients with short bowel syndrome with colorectal continuity |
| ATE498631T1 (en) * | 2005-05-04 | 2011-03-15 | Zealand Pharma As | GLUCAGON LIKE PEPTIDE 2 (GLP-2) ANALOGUE |
| CN101331224A (en) * | 2005-10-24 | 2008-12-24 | 森托科尔公司 | GLP-2 mimetibodies, polypeptides, compositions, methods and uses |
| CN101573376B (en) * | 2006-11-08 | 2013-11-06 | 西兰制药公司 | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| CA2848204C (en) * | 2011-09-12 | 2023-04-04 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
| CN104540850B (en) * | 2012-05-03 | 2018-05-18 | 西兰制药公司 | Glucagon-like peptide 2 (GLP-2) analog |
| US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
| KR20210126088A (en) * | 2019-02-11 | 2021-10-19 | 옵코 바이오로직스 리미티드 | long-acting GLP-2 analogues |
-
2018
- 2018-06-15 CN CN201880053014.6A patent/CN111032072A/en active Pending
- 2018-06-15 BR BR112019026711-5A patent/BR112019026711A2/en unknown
- 2018-06-15 ES ES18734135T patent/ES2894629T3/en active Active
- 2018-06-15 IL IL299864A patent/IL299864B2/en unknown
- 2018-06-15 KR KR1020207001446A patent/KR102504200B1/en active IP Right Grant
- 2018-06-15 CN CN202410762243.2A patent/CN118526577A/en active Pending
- 2018-06-15 PE PE2019002548A patent/PE20200678A1/en unknown
- 2018-06-15 DK DK21150552.4T patent/DK3881861T3/en active
- 2018-06-15 IL IL271245A patent/IL271245B2/en unknown
- 2018-06-15 EP EP24182737.7A patent/EP4424362A2/en active Pending
- 2018-06-15 EP EP21150552.4A patent/EP3881861B1/en active Active
- 2018-06-15 KR KR1020237006296A patent/KR20230035677A/en not_active Application Discontinuation
- 2018-06-15 MX MX2019015054A patent/MX2019015054A/en unknown
- 2018-06-15 TW TW107120806A patent/TWI791539B/en active
- 2018-06-15 SG SG11201912161SA patent/SG11201912161SA/en unknown
- 2018-06-15 WO PCT/EP2018/065951 patent/WO2018229252A1/en active Application Filing
- 2018-06-15 AU AU2018285580A patent/AU2018285580B2/en active Active
- 2018-06-15 DK DK18734135.9T patent/DK3638291T3/en active
- 2018-06-15 EP EP18734135.9A patent/EP3638291B1/en active Active
- 2018-06-15 CA CA3066523A patent/CA3066523A1/en active Pending
- 2018-06-15 JP JP2020519850A patent/JP7200238B2/en active Active
-
2019
- 2019-07-15 US US16/511,766 patent/US20200000883A1/en active Pending
- 2019-12-12 CO CONC2019/0014028A patent/CO2019014028A2/en unknown
- 2019-12-13 ZA ZA2019/08355A patent/ZA201908355B/en unknown
- 2019-12-13 CL CL2019003660A patent/CL2019003660A1/en unknown
- 2019-12-13 MX MX2023003828A patent/MX2023003828A/en unknown
-
2022
- 2022-12-20 JP JP2022203265A patent/JP7566859B2/en active Active
-
2024
- 2024-04-16 AU AU2024202486A patent/AU2024202486B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271245A (en) | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues | |
| GB201807942D0 (en) | Pharmaceutical formulation | |
| ZA201906613B (en) | Pharmaceutical compositions for combination therapy | |
| ZA201905510B (en) | Pharmaceutical compositions for combination therapy | |
| IL271226A (en) | Pharmaceutical formulation | |
| EP3263155A4 (en) | Drug solution administering device | |
| IL279127A (en) | Delivery devices for administering drugs | |
| ZA202102871B (en) | Pharmaceutical formulation | |
| SG11202010124SA (en) | Stable pharmaceutical formulation | |
| HK1248544A1 (en) | Stable pharmaceutical composition for oral administration | |
| IL278927A (en) | Pharmaceutical formulation | |
| EP3351286A4 (en) | Device for administering drug solution | |
| LT3601277T (en) | Pharmaceutical formulation | |
| IL268708B (en) | Pharmaceutical compositions for combination therapy | |
| HK1259373A1 (en) | Pharmaceutical formulations for the treatment of diabetes | |
| IL275144A (en) | Pharmaceutical formulation | |
| GB201709643D0 (en) | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues | |
| GB201800873D0 (en) | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues | |
| EP3697393A4 (en) | Pharmaceutical dosage forms | |
| EP3675842A4 (en) | Pharmaceutical dosage forms | |
| PT3650024T (en) | Pharmaceutical composition for nasal administration | |
| GB201714203D0 (en) | Dosage regimes for the administration of Glucagon-Like Peptide-2(GLP-2)Analogues | |
| IL279128A (en) | Delivery devices for administering drugs | |
| PL3655075T3 (en) | Nebulization device for medical mixture | |
| GB201719873D0 (en) | Pharmaceutical formulation |